Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 480

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 480
---
000 purchase price consideration to the royalty agreement.

On December 12, 2024,
TuHURA announced that it had entered into the Merger Agreement for the acquisition of Kineta via a merger transaction. The Merger Agreement contemplates that, at the closing of the merger transaction, Hura Merger Sub I will (a) merge with and
into Kineta, with Kineta being the surviving corporation of the First Merger, and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Entity will merge with and into Hura Merger
Sub II, with Hura Merger Sub II being the surviving company of the Second Merger.

At the effective time of the First Merger, and subject
to the terms and conditions of the Merger Agreement, each share of Kineta Common Stock issued and outstanding immediately prior to the effective time of the First Merger will be converted automatically into and will represent the right to receive,
without interest, the number of shares of TuHURA Common Stock and cash consideration each calculated according to the terms of the Merger Agreement. The proposed Kineta Merger currently is expected to be consummated in the second quarter of 2025,
subject to the satisfaction or waiver of closing conditions (including the financing condition) under the Merger Agreement.

305

Clinical Trial Funding Agreement In connection with the Merger Agreement, TuHURA entered into a Clinical Trial Funding Agreement (the “CTF Agreement”) with Kineta under which TuHURA agreed to continue to fund clinical trial expenses for KVA12123 in an amount of up to $900,000, which may be increased upon mutual agreement. Pursuant to the terms of the CTF Agreement, Kineta granted a security interest to TuHURA in the assets, rights, including patents, patent rights, patent application, product and development program assets, and other rights and assets, associated with, derived from, relating to, or used in connection with KVA12123 and the KVA12123 development program and clinical trial. Any amounts loaned to Kineta under the CTF Agreement will be evidenced by a secured promissory note, bearing interest at 5% simple interest per annum, payable on the earlier of (a) following the closing of the Kineta Merger, any date on which we demand payment by written notice to Kineta or (b) if the Merger Agreement is terminated, within ten days following the date of such termination